Johnson Pharmacare
JOHNSONPHARMACARELTD NSE
Johnson Pharmacare
Commercial ServicesNSE: JOHNSONPHARMACARELTD BSE: 532154 Diversified Services
Key Fundamentals
MicrocapDiversified ServicesCommercial ServicesMarket Cap
₹25.85 Cr
Volatility
Moderate
P/E Ratio
-0.4
EBITDA
₹-57.05 Cr
Return on Equity
-1.04%
Debt to Equity
0.02
Book Value
₹0.01
EPS
₹0
52W High
₹0.8
52W Low
₹0.45
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
3- Stock is trading at 57.5 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -29.6% over last 3 years.
Growth Rate
Revenue Growth
—
Net Income Growth
—
Cash Flow Change
—
ROE
197% higher than
3Y
ROCE
212% higher than
3Y
EBITDA Margin (Avg.)
—
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.19 | 0 | 0 | 0 | 0.04 | 0 | 0.03 | 0.01 | 0.05 | 0 | 0.02 | 42.7 | 0.04 |
| Operating Profit | -0.19 | 0 | 0 | 0 | -0.04 | 0 | -0.03 | -0.01 | -0.05 | 0 | -0.02 | -42.7 | -0.04 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.5 | 0 | 0 | 0 | -12.69 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.04 | 0.22 | 1.06 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.19 | 0 | 0 | 0 | -0.04 | 0 | -0.03 | -0.51 | -0.05 | 0 | -0.06 | -55.61 | -1.1 |
| Tax % | 0% | — | — | — | 0% | — | 0% | 0% | 0% | — | 0% | 0% | 0% |
| Net Profit | -0.19 | 0 | 0 | 0 | -0.04 | 0 | -0.03 | -0.51 | -0.05 | 0 | -0.06 | -55.61 | -1.1 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.01 | 0 | 0 | 0 | -1.01 | -0.02 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 3 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 43 | 43 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -43 | -43 |
| OPM % | — | — | — | — | -1.1% | — | 0% | 4% | 9% | — | — | — | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | -13 | -13 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | -1 | -56 | -57 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | — | 31% | -3% | 0% | 0% | 0% | — |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | -1 | -56 | -57 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.02 | 0 | -0.01 | -1.01 | -1.03 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 55 | 55 | 55 | 55 | 55 |
| Reserves | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 3 | 2 | 2 | 1 | -55 |
| Borrowings | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 1 | 21 |
| Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Total Liabilities | 60 | 59 | 59 | 60 | 60 | 59 | 59 | 60 | 60 | 60 | 58 | 22 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 54 | 43 | 54 | 54 | 53 | 52 | 52 | 54 | 46 | 46 | 42 | 20 |
| Other Assets | 6 | 16 | 5 | 6 | 7 | 7 | 7 | 6 | 14 | 14 | 16 | 2 |
| Total Assets | 60 | 59 | 59 | 60 | 60 | 59 | 59 | 60 | 60 | 60 | 58 | 22 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 8 | -11 | 11 | -1 | -1 | 0 | 0 | 5 | 0 | 0 | -2 | -57 |
| Investing | 10 | 11 | -11 | 0 | 1 | 1 | 0 | -5 | -1 | 0 | 3 | 58 |
| Financing | 2 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 1 | 0 | -1 | 0 |
| Net Cash Flow | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 8 | -11 | 11 | -1 | -1 | 0 | 0 | 5 | 0 | 0 | -2 | -57 |
| CFO/OP | -41,350 | 8,385 | -8,200 | 1,417 | 9,300 | -189 | — | 3,800 | -200 | 25 | 764 | 134 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | — | — | — | 365 | — | 807 | 118 | 0 | — | — | — |
| Inventory Days | — | — | — | — | — | — | 0 | 0 | 0 | — | — | — |
| Cash Conversion Cycle | — | — | — | — | 365 | — | 807 | 118 | 0 | — | — | — |
| Working Capital Days | — | — | — | — | 1,932 | — | 2,267 | -9 | -141 | — | — | — |
| ROCE % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -105% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Johnson Pharmacare insights
62 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
2d - Company confirms it is not a Large Corporate for year ended March 31, 2026. 2d - Company confirms it is not a Large Corporate for year ended March 31, 2026.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Johnson Pharmacare confirms it is not a Large Corporate for FY 2025-26 under SEBI debt rules. 30 Apr - Johnson Pharmacare confirms it is not a Large Corporate for FY 2025-26 under SEBI debt rules.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Johnson Pharmacare confirms it is not a Large Corporate for FY 2025-26 under SEBI debt rules. 30 Apr - Johnson Pharmacare confirms it is not a Large Corporate for FY 2025-26 under SEBI debt rules.
4
Board Meeting Outcome for Outcome Of Meeting Of Board Pursuant To Regulation 30 Of The SEBI
(LODR) Regulations, 2015.
17 Apr - Board appointed two additional directors and approved two director resignations effective 17 April 2026. 17 Apr - Board appointed two additional directors and approved two director resignations effective 17 April 2026.
5
Announcement under Regulation 30 (LODR)-Change in Management
17 Apr - On 17 Apr 2026, board appointed Nand Kishore Ray and Dheeraj Kumar as additional directors. 17 Apr - On 17 Apr 2026, board appointed Nand Kishore Ray and Dheeraj Kumar as additional directors.
Frequently Asked Questions about Johnson Pharmacare
What does Johnson Pharmacare Ltd do?
Johnson Pharmacare Limited, formerly Sun
and Shine Worldwide Limited, is an investment-focused listed company with no demonstrated pharmaceutical operations.
Where is Johnson Pharmacare Ltd (532154) listed?
Johnson Pharmacare Ltd trades as JOHNSONPHARMACARELTD on the NSE and under code 532154 on the BSE.
Which sector does Johnson Pharmacare Ltd belong to?
Johnson Pharmacare Ltd is classified under the Commercial Services sector, in the Diversified Services industry.
What is the market capitalisation of Johnson Pharmacare Ltd?
Johnson Pharmacare Ltd has a market capitalisation of ₹25.85 Cr, which places it in the Small Cap band.
What is the PE ratio of Johnson Pharmacare Ltd?
Johnson Pharmacare Ltd trades at a PE ratio of -0.40, on earnings per share of ₹0, against a book value of ₹0.01 per share.
What is the 52-week high and low of Johnson Pharmacare Ltd?
Over the last 52 weeks Johnson Pharmacare Ltd has traded between ₹0.45 and ₹0.8.
What is the Return on Equity (ROE) of Johnson Pharmacare Ltd?
Johnson Pharmacare Ltd reported a return on equity of -1.04%. Its debt-to-equity ratio is 0.02.
Company Information
Johnson Pharmacare Limited, formerly Sun and Shine Worldwide Limited, is an investment-focused listed company with no demonstrated pharmaceutical operations.
Face Value ₹ 1
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/532154.md for Johnson Pharmacare Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.